Cover - USD ($) |
12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2025 |
Mar. 19, 2026 |
Jun. 30, 2025 |
|
| Cover [Abstract] | |||
| Document Type | 10-K | ||
| Document Annual Report | true | ||
| Document Period End Date | Dec. 31, 2025 | ||
| Current Fiscal Year End Date | --12-31 | ||
| Document Transition Report | false | ||
| Entity File Number | 001-38613 | ||
| Entity Registrant Name | Bionano Genomics, Inc. | ||
| Entity Incorporation, State or Country Code | DE | ||
| Entity Tax Identification Number | 26-1756290 | ||
| Entity Address, Address Line One | 9540 Towne Centre Drive | ||
| Entity Address, Address Line Two | Suite 100 | ||
| Entity Address, City or Town | San Diego | ||
| Entity Address, State or Province | CA | ||
| Entity Address, Postal Zip Code | 92121 | ||
| City Area Code | 858 | ||
| Local Phone Number | 888-7600 | ||
| Title of 12(b) Security | Common Stock, $0.0001 par value | ||
| Trading Symbol | BNGO | ||
| Security Exchange Name | NASDAQ | ||
| Entity Well-known Seasoned Issuer | No | ||
| Entity Voluntary Filers | No | ||
| Entity Current Reporting Status | Yes | ||
| Entity Interactive Data Current | Yes | ||
| Entity Filer Category | Non-accelerated Filer | ||
| Entity Small Business | true | ||
| Entity Emerging Growth Company | false | ||
| ICFR Auditor Attestation Flag | false | ||
| Document Financial Statement Error Correction | false | ||
| Entity Shell Company | false | ||
| Entity Public Float | $ 12,154,000 | ||
| Entity Common Stock, Shares Outstanding (in shares) | 11,092,000 | ||
| Documents Incorporated by Reference | Portions of the definitive proxy statement, or the Proxy Statement, for the Registrant’s 2026 Annual Meeting of Stockholders are incorporated by reference into Part III of this Annual Report on Form 10-K. The Proxy Statement will be filed with the Securities and Exchange Commission within 120 days of the Registrant’s fiscal year ended December 31, 2025. |
||
| Entity Central Index Key | 0001411690 | ||
| Document Fiscal Year Focus | 2025 | ||
| Document Fiscal Period Focus | FY | ||
| Amendment Flag | false | ||
| Auditor Name | BDO USA, P.C. | ||
| Auditor Location | San Diego, California | ||
| Auditor Firm ID | 243 | ||
| Auditor Opinion | Opinion on the Consolidated Financial Statements We have audited the accompanying consolidated balance sheets of Bionano Genomics, Inc. (the “Company”) as of December 31, 2025 and 2024, the related consolidated statements of operations, comprehensive loss, stockholders’ equity, and cash flows for each of the years then ended, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2025 and 2024, and the results of its operations and its cash flows for each of the years then ended, in conformity with accounting principles generally accepted in the United States of America. |